| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
trans-Chalcone targets fatty acid synthase (FASN), α-amylase, and α7 nicotinic acetylcholine receptors. It is a positive allosteric modulator of α7 nicotinic acetylcholine receptors. The compound also targets apoptosis pathways.
|
|---|---|
| ln Vitro |
Porcine pancreatic α-amylase is competitively inhibited by trans-chalcone, with a Ki of 48 μM[2]. In MCF-7 cells, trans-Chalcone (30.23-98.03 μM; 24 hours) causes cell cycle arrest and apoptosis[1]. Bcl-2, a protein associated to apoptosis, is expressed less when trans-Chalcone (20-80 μM; 24–48 hours) is applied[1]. In a 24-hour period, trans-Chalcone (58.25 μM; 6) exhibits a stronger induction of CIDEA, a stronger inhibition of Bcl-2, and an induction of APAF1 and BAX. MCF-7 cell viability is inhibited by trans-Chalcone (24 hours) (IC20=30.23 μM; IC50=58.25 μM; IC80=98.03 μM). For the MCF-7 and 3T3 cell lines, trans-Chalcone (48 h) had IC50s of 41.53 μM and 48.41 μM, respectively. There is a noticeable cytotoxic action of trans-Chalcone[1].
trans-Chalcone is a potent fatty acid synthase (FAS) and α-amylase inhibitor. It causes cell cycle arrest and induces apoptosis in MCF-7 breast cancer cells. The compound has antifungal and anticancer activity. It induces programmed cell death due to reduced mitochondrial transmembrane potential. |
| ln Vivo |
trans-Chalcone is used to prevent lung and forestomach cancer. It induces programmed cell death in Arabidopsis thaliana roots. The compound has been studied for its chemopreventive and anticancer properties.
|
| Enzyme Assay |
In vitro enzyme assays measure fatty acid synthase and α-amylase inhibition. Receptor binding assays assess positive allosteric modulation of α7 nicotinic acetylcholine receptors.
|
| Cell Assay |
Apoptosis Analysis[1]
Cell Types: MCF-7 cell Tested Concentrations: 30.23, 58.25, 98.03 μM Incubation Duration: 24 hrs (hours) Experimental Results: Induced apoptosis of the breast cancer cell line. Cell Cycle Analysis[1] Cell Types: MCF-7 cell Tested Concentrations: 30.23, 58.25, 98.03 μM Incubation Duration: 24 hrs (hours) Experimental Results: Caused cell cycle arrest in G1. Western Blot Analysis[1] Cell Types: MCF-7 cell Tested Concentrations: 20, 40, 80 μM Incubation Duration: 24, 48 hrs (hours) Experimental Results: decreased the expression of the apoptosis-related protein Bcl-2 and induced the expression of the CIDEA gene. There was marked degradation of cyclin D1 at 48 h. RT-PCR[1] Cell Types: MCF- 7 cell Tested Concentrations: 58.25 μM Incubation Duration: 6, 24 hrs (hours) Experimental Results: Had greater inhibition of Bcl-2, induction of APAF1 and BAX, and strong induction of CIDEA in 24 hrs (hours). Cell-based assays use MCF-7 breast cancer cells to measure cell cycle arrest and apoptosis induction. The compound's effects on mitochondrial transmembrane potential are assessed. Antifungal activity is evaluated against fungal pathogens. |
| Animal Protocol |
In vivo efficacy is evaluated in animal models of cancer. The compound's ability to prevent lung and forestomach cancer is assessed. Further studies are needed to fully characterize its in vivo anticancer activity and pharmacokinetic properties.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for trans-chalcone are limited. As a natural chalcone, its absorption, distribution, metabolism, and excretion properties have not been extensively characterized. Further pharmacokinetic studies are needed to determine its bioavailability.
|
| Toxicity/Toxicokinetics |
Toxicological data for trans-chalcone are limited. As a natural product, its safety profile has not been fully established. Standard laboratory safety precautions should be followed when handling this compound. Further toxicity studies are needed.
|
| References |
|
| Additional Infomation |
Chalcone is a type of chalcone compound with a structure similar to acetophenone, except that one methyl hydrogen atom is replaced by a benzylidene group. It is a plant metabolite belonging to the styrene and chalcone classes. Chalcone has been reported to exist in Alpinia hainanensis, Xanthorrhoea latifolia, and other organisms with relevant data. Chalcone is an aromatic ketone, and the core molecule of the chalcone group is an aromatic ketone.
trans-Chalcone is a potent fatty acid synthase and α-amylase inhibitor and a positive allosteric modulator of α7 nicotinic acetylcholine receptors. It causes cell cycle arrest and induces apoptosis in breast cancer cells. The compound has antifungal, anticancer, and antioxidant activities. It is a valuable research tool for studying cancer, metabolism, and receptor pharmacology. |
| Molecular Formula |
C15H12O
|
|---|---|
| Molecular Weight |
208.26
|
| Exact Mass |
208.088
|
| CAS # |
614-47-1
|
| Related CAS # |
Chalcone;94-41-7
|
| PubChem CID |
637760
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
346.6±25.0 °C at 760 mmHg
|
| Melting Point |
55-57ºC
|
| Flash Point |
150.1±18.1 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.625
|
| LogP |
4.01
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
16
|
| Complexity |
242
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)/C=C/C(=O)C2=CC=CC=C2
|
| InChi Key |
DQFBYFPFKXHELB-VAWYXSNFSA-N
|
| InChi Code |
InChI=1S/C15H12O/c16-15(14-9-5-2-6-10-14)12-11-13-7-3-1-4-8-13/h1-12H/b12-11+
|
| Chemical Name |
(E)-1,3-diphenylprop-2-en-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (480.17 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (12.00 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (12.00 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (12.00 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.8017 mL | 24.0085 mL | 48.0169 mL | |
| 5 mM | 0.9603 mL | 4.8017 mL | 9.6034 mL | |
| 10 mM | 0.4802 mL | 2.4008 mL | 4.8017 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
